This report discusses the case of an 86-year-old man with a full-thickness macular hole (FTMH) secondary to polypoidal choroidal vasculopathy (PCV) treated with bevacizumab.
Methods:
A case report is presented.
Results:
An 86-year-old man presented with a 5-month history of metamorphopsia and decreased vision in his right eye and was found to have active exudation secondary to PCV with a concurrent FTMH. After 4 treatments with intravitreal bevacizumab, the FTMH resolved without surgical intervention.
Conclusions:
The patient’s FTMH resolved with solely pharmacologic treatment as a result of treating his PCV with intravitreal bevacizumab. Macular hole formation secondary to PCV is a rare finding, but may be successfully treated with pharmacologic therapy without surgical intervention.
KokameGT. Polypoidal choroidal vasculopathy—a type I polypoidal subretinal neovasculopathy. Open Ophthalmol J. 2013;7:82–84. doi:10.2174/1874364101307010082
AhujaRMStangaPEVingerlingJRReckACBirdAC. Polypoidal choroidal vasculopathy in exudative and haemorrhagic pigment epithelial detachments. Br J Ophthalmol. 2000;84(5):479–484. doi:10.1136/bjo.84.5.479
4.
YunCKimSWHuhKOhJ. Macular hole closure following anti-vascular endothelial growth factor injection in an eye with myopic choroidal neovascularization. Int J Ophthalmol. 2016;9(9):1364–1366. doi:10.18240/ijo.2016.09.24
5.
StorchMWHoeraufH. Case report of a secondary macular hole closure after intravitreal bevacizumab therapy in a patient with retinal pigment epithelial detachment. Indian J Ophthalmol. 2017;65(7):632–633. doi:10.4103/ijo.IJO_818_16
6.
SuDKlufasMAHubschmanJP. Spontaneous closure of a full-thickness macular hole with conversion to exudative age-related macular degeneration. JAMA Ophthalmol. 2016;134(5):604–606. doi:10.1001/jamaophthalmol.2016.0020
7.
LamDSrourMSemounOTilleulJSouiedEH. Resolution of a macular hole complicating a pseudophakic macular edema with nonsurgical treatment. Retin Cases Brief Rep. 2018;12(2):131–135. doi: 10.1097/ICB.0000000000000446
8.
SugiyamaAImasawaMChibaTIijimaH. Reappraisal of spontaneous closure rate of idiopathic full-thickness macular holes. Open Ophthalmol J. 2012;6:73–74. doi:10.2174/1874364101206010073
9.
BankerASFreemanWRKimJWMunguiaDAzenSP. Vision-threatening complications of surgery for full-thickness macular holes. Vitrectomy for Macular Hole Study Group. Ophthalmology. 1997;104(9):1442–1452; discussion 1452-1453. doi:10.1016/s0161-6420(97)30118-3
10.
BaskaranPPanU. Macular hole secondary to polypoidal choroidal vasculopathy. Middle East Afr J Ophthalmol. 2017;24(3):159–161. doi:10.4103/meajo.MEAJO_30_16
11.
KumawatDVenkateshPBrarAS, et al.Atypical macular holes. Retina. 2019;39(7):1236–1264. doi:10.1097/IAE.0000000000002448
12.
SuDObeidAHsuJ. Topical aqueous suppression and closure of idiopathic full-thickness macular holes. Ophthalmic Surg Lasers Imaging Retina. 2019;50(2):e38–e43. doi:10.3928/23258160-20190129-17
13.
CheungCMGLaiTYYRuamviboonsukP, et al.Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology. 2018;125(5):708–724. doi:10.1016/j.ophtha.2017.11.019
14.
KohALeeWKChenLJ, et al.EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453–1464. doi:10.1097/IAE.0b013e31824f91e8
15.
KohALaiTYYTakahashiK, et al.Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135(11):1206–1213. doi:10.1001/jamaophthalmol.2017.4030
